Clinical trials: Rosacea
Rosacea
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea.
- Trial name
- NCT04886739
- Testing
- CGB-400, Vehicle Gel
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- CAGE Bio Inc.
Erythema, Rosacea
Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
This is a study to evaluate inter- and intra-rater reliability of the Clinician Erythema Assessment Scale. There is no treatment (intervention) associated with this study.
- Trial name
- NCT01636765
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Allergan
Rosacea, Vascular Diseases
Vbeam Pro Pulse Dye Laser for the Treatment of Vascular Conditions
This is a clinical study to evaluate the safety and performance of the Vbeam Pro Laser System for the treatment of vascular indications, including rosacea and port wine stain birthmarks.
- Conditions
- Rosacea, Vascular Diseases, Port-Wine Stain
- Trial name
- NCT07290426
- Testing
- Vbeam Pro Laser Treatment
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Rosacea
A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)
This study will assess the effect of MK-0524 relative to placebo, on signs and symptoms of rosacea and to determine the safety and tolerability profile of MK-0524 in participants with rosacea.
- Trial name
- NCT01451619
- Testing
- Laropiprant
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Rosacea
The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea
This study evaluates a nature-based sensitive skin regimen (NBSSR), as a suitable adjunct topical application to prescription medication when administered daily over the course of four weeks, in moderate to severe rosacea in…
- Trial name
- NCT03392558
- Testing
- Burt's Bees Skin Care Regimen, Control Regimen
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Burt's Bees Inc.
Papulopustular Rosacea
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel. Assessment of safety after repeated skin application.
- Trial name
- NCT01257919
- Testing
- Azelaic Acid Foam, Azelaic Acid Gel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- LEO Pharma
Rosacea
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
- Trial name
- NCT03689010
- Testing
- Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
- Where
- United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Rosacea
Preferences & Treatment Satisfaction Drivers in Rosacea Patients
To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.
- Trial name
- NCT02602470
- Testing
- Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- LEO Pharma
Rosacea
Assessment of the Rosacea Prevalence in the General Population
Multi-centre interventional cross-sectional prevalence study Assessment of the Rosacea Prevalence in the General Population.
- Trial name
- RISE (NCT02292797)
- Testing
- Prevalence assessment
- Volunteers
- 6,000 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea. The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release…
- Trial name
- NCT03864978
- Testing
- Rifaximin delayed release 400 mg tablet
- Where
- 12 sites in Italy
- Volunteers
- 236 people
- Sponsor
- Alfasigma S.p.A.
Inflammatory Rosacea
Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
The aim of this trial is to assess the efficacy of Metronidazole Topical Gel 1% in the Treatment of Inflammatory Lesions of Rosacea.
- Trial name
- NCT01016782
- Testing
- 0444
- Volunteers
- 867 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Acne, Atopic Dermatitis
Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected.
- Conditions
- Acne, Atopic Dermatitis, Psoriasis Vulgaris, Rosacea
- Trial name
- NCT04472546
- Testing
- in-vivo mesure, Scotch, Lipid index
- Where
- France
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Erythematous Rosacea
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
- Trial name
- NCT00697541
- Testing
- 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Rosacea Subtype 1 (Erythematotelangiectatic)
Efficacy and Tolerability of Topical Rossoseq™ Compared to Vehicle in Rosacea Subtype 1 (Erythematotelangiectatic)
Rossoseq™ is registered for the treatment of inflammatory skin conditions. Rosacea is one such inflammatory skin disorder that has not been studied yet for the use of Rossoseq™.
- Trial name
- NCT01666509
- Testing
- Rossoseq™
- Where
- 4 sites in Germany
- Volunteers
- 61 people
- Sponsor
- PBB Entrepreneur Ltd.
Papulopustular Rosacea
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01494467
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 688 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03564119
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle.
- Trial name
- PRISM (NCT03667222)
- Testing
- minocycline topical gel, topical gel vehicle
- Where
- 12 sites in United States
- Volunteers
- 207 people
- Sponsor
- BioPharmX, Inc.
Rosacea
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
- Trial name
- NCT05597462
- Testing
- Minocycline hydrochloride capsules
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Journey Medical Corporation
Papulopustular Rosacea
A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus twice daily in the treatment of patients with papulopustular rosacea.
- Trial name
- NCT00417937
- Testing
- azelaic acid 15% gel
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- LEO Pharma